Quarterly report · Q2
6776.TEDINET S100PKUV
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥10.9bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥19.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥8.6bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥266m | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥19m | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥445m | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥355m | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥81m | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥464m | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥92m | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥329m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥246m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥20m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥311m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥37m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥23.3bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥21.3bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥19.9bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥13.9bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥13.2bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥9.3bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥8.1bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥7.3bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.7bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.0bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥3.8bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.7bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥472m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥831m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.9bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥456m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥544m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥545m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥399m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥19.39 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥13.23 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥14.47 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥1.23 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-0.66 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 33.1% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.1% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.2% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 42
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥59m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥59m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | ¥2m |
| jpcrp040300-q2r_E01813-000Injection Molding Business In Americareportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E01813-000Injection Molding Business In Americareportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E01813-000Injection Molding Business In Americareportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥26m |
| jpcrp040300-q2r_E01813-000Injection Molding Business In Chinareportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥430m |
| jpcrp040300-q2r_E01813-000Injection Molding Business In Chinareportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥389m |
| jpcrp040300-q2r_E01813-000Injection Molding Business In Chinareportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥40m |
| jpcrp040300-q2r_E01813-000Injection Molding Business In Chinareportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥65m |
| jpcrp040300-q2r_E01813-000Injection Molding Business In Japanreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥9.1bn |
| jpcrp040300-q2r_E01813-000Injection Molding Business In Japanreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥9.1bn |
| jpcrp040300-q2r_E01813-000Injection Molding Business In Japanreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥18m |
| jpcrp040300-q2r_E01813-000Injection Molding Business In Japanreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥107m |
| jpcrp040300-q2r_E01813-000Real Estate Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥143m |
| jpcrp040300-q2r_E01813-000Real Estate Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥143m |
| jpcrp040300-q2r_E01813-000Real Estate Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥117m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥11.0bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥10.9bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥59m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥263m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥19m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥19m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥3m |
| jpcrp040300-q2r_E01813-000Injection Molding Business In Americareportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E01813-000Injection Molding Business In Americareportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E01813-000Injection Molding Business In Americareportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥51m |
| jpcrp040300-q2r_E01813-000Injection Molding Business In Chinareportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥222m |
| jpcrp040300-q2r_E01813-000Injection Molding Business In Chinareportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥221m |
| jpcrp040300-q2r_E01813-000Injection Molding Business In Chinareportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥1m |
| jpcrp040300-q2r_E01813-000Injection Molding Business In Chinareportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥17m |
| jpcrp040300-q2r_E01813-000Injection Molding Business In Japanreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥7.1bn |
| jpcrp040300-q2r_E01813-000Injection Molding Business In Japanreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥7.1bn |
| jpcrp040300-q2r_E01813-000Injection Molding Business In Japanreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥17m |
| jpcrp040300-q2r_E01813-000Injection Molding Business In Japanreportable segment | segment profit | 2021-04-01 → 2021-09-30 | −¥163m |
| jpcrp040300-q2r_E01813-000Real Estate Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥144m |
| jpcrp040300-q2r_E01813-000Real Estate Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥144m |
| jpcrp040300-q2r_E01813-000Real Estate Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥117m |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥8.6bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥8.6bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥19m |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥22m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 501
| Item | Context | Value | Unit |
|---|---|---|---|
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |